Bayer will discontinue phase II development candidate eliapixant
Review of development program led to reassessment of benefit-risk ratio in all four potential indications for ...
Read moreReview of development program led to reassessment of benefit-risk ratio in all four potential indications for ...
Read moreBayer today announced Christine Roth as the new Head of the Oncology Strategic Business Unit at ...
Read moreBayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. and ...
Read moreAtal Innovation Mission (AIM), NITI Aayog today collaborated with Bayer- a global enterprise with core competencies ...
Read moreIn the Phase III trial CHRONOS-3 of 458 patients with indolent non-Hodgkin’s Lymphoma (iNHL), the investigational ...
Read moreBayer announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.